Low-dose priming before vaccination with the phase I chloroform-methanol residue vaccine against Q fever enhances humoral and cellular immune responses to Coxiella burnetii

Clinical and Vaccine Immunology

Volumn 15, Issue 10, 2008, Pages 1505-1512

  Waag, David M ^a   England, Marilyn J ^a   Bolt, Christopher R ^a   Williams, Jim C ^a,b  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Opexa Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ANTIGEN; PHASE I CHLOROFORM METHANOL RESIDUE VACCINE; Q FEVER VACCINE; UNCLASSIFIED DRUG; BACTERIAL VACCINE; BACTERIUM ANTIBODY; PLACEBO;

ADULT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CELL ACTIVATION; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COXIELLA BURNETII; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; LOW DRUG DOSE; MALE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; Q FEVER; VACCINATION; ANIMAL; BLOOD; CELL CULTURE; CHEMISTRY; CHICK EMBRYO; IMMUNIZATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE;

ADULT; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; CELLS, CULTURED; CHICK EMBRYO; COXIELLA BURNETII; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNIZATION, SECONDARY; INJECTIONS, SUBCUTANEOUS; LYMPHOCYTE ACTIVATION; MALE; PLACEBOS; Q FEVER; T-LYMPHOCYTES; VACCINATION;

EID: 55449097339     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00119-08     Document Type: Article

References (43)

1. Ackland, J. R., D. A. Worswick, and B. P. Marmion. 1994. Vaccine prophylaxis of Q fever. A follow-up study of the efficacy of Q-Vax (CSL) 1985-1990. Med. J. Aust. 160:704-708.
2. Amano, K., and J. C. Williams. 1984. Chemical and immunological characterization of lipopolysaccharides from phase I and phase II Coxiella burnetii. J. Bacteriol. 160:994-1002.
3. Bell, J. F., D. B. Lackman, A. Meis, and W. J. Hadlow. 1964. Recurrent reaction of site of Q fever vaccination in a sensitized person. Mil. Med. 129:591-595.
4. Benenson, A. S. 1959. Q fever vaccine: efficacy and present status, p. 47-60. In J. E. Smadel (ed.), Symposium on Q fever. Walter Reed Army Institute of Medical Science publication no. 6. Government Printing Office, Washington, DC.
5. Brezina, R., S. Schramek, J. Kazar, and J. Urovolgyi. 1974. Q fever chemovaccine for human use. Acta Virol. 18:269.
6. Brooks, D. L., R. W. Ermel, C. E. Franti, R. Ruppanner, D. E. Behymer, J. C. Williams, E. H. Stephenson, and J. C. Stephenson. 1986. Q fever vaccination of sheep: challenge of immunity in ewes. Am. J. Vet. Res. 47:1235-1238.
7. Burnet, F. M., and M. Freeman. 1937. Experimental studies on the virus of "Q" fever. Med. J. Aust. 2:299-305.
8. Derrick, E. H. 1937. Q fever, a new fever entity: clinical features, diagnosis and laboratory investigation. Med. J. Aust. 2:281-299.
9. Dupuis, G., O. Peter, M. Peacock, W. Burgdorfer, and E. Haller. 1985. Immunoglobulin responses in acute Q fever. J. Clin. Microbiol. 22:484-487.
10. Embil, J., J. C. Williams, and T. J. Marrie. 1990. The immune response in a cat-related outbreak of Q fever as measured by the indirect immunofluorescence test and the enzyme-linked immunosorbent assay. Can. J. Microbiol. 36:292-296.
11. Fiset, P. 1966. Vaccination against Q fever, p. 528-531. In Vaccines against viral and rickettsial diseases in man. PAHO science publication number 147. Pan American Health Organization, Washington, DC.
12. Fries, L. F., D. M. Waag, and J. C. Williams. 1993. Safety and immunogenicity in human volunteers of a chloroform-methanol residue vaccine for Q fever. Infect. Immun. 61:1251-1258.
13. Genig, V. A. 1965. Experience in mass immunization of humans with the M-44 live vaccine against Q-fever. 2. Skin and oral routes of immunization. Vopr. Virusol. 10:703-707.
14. Johnson, J. W., G. A. Eddy, and C. E. Pedersen, Jr. 1976. Biological properties of the M-44 strain of Coxiella burnetii. J. Infect. Dis. 133:334-338.
15. Kishimoto, R. A., J. C. Gonder, J. W. Johnson, J. A. Reynolds, and E. W. Larson. 1981. Evaluation of a killed phase I Coxiella burnetii vaccine in cynomolgus monkeys (Macaca fascicularis). Lab. Anim. Sci. 31:48-51.
16. Koster, F. T., J. C. Williams, and J. S. Goodwin. 1985. Cellular immunity in Q fever: modulation of responsiveness by a suppressor T cell-monocyte circuit. J. Immunol. 135:1067-1072.
17. Lackman, D., E. J. Bell, J. F. Bell, and E. Pickens. 1962. Intradermal sensitivity testing in man with a purified vaccine for Q fever. Am. J. Public Health 52:87-93.
18. Luoto, L., J. F. Bell, M. L. Casey, and D. B. Lackman. 1963. Q fever vaccination of human volunteers. I. The serologic and skin test response following subcutaneous injections. Am. J. Hyg. 78:1-15.
19. Ormsbee, R., and B. Marmion. 1990. Prevention of Coxiella burnetii infection: vaccines and guidelines for those at risk, p. 225-248. In T. Marrie (ed.), Q fever. The disease, vol. I. CRC Press, Boca Raton, FL.
20. Ormsbee, R. A., E. J. Bell, and D. B. Lackman. 1962. Antigens of Coxiella burnetii. I. Extraction of antigens with non-aqueous organic solvents. J. Immunol. 88:741-749.
21. Ormsbee, R. A., E. J. Bell, D. B. Lackman, and G. Tallent. 1964. The influence of phase on the protective potency of Q fever vaccine. J. Immunol. 92:404-412.
22. Pollok, N. L. 1965. Mixed infections of staphylococcal enterotoxin B, VEE, and Q fever in Macaca mullata monkeys, p. 19. Technical manuscript no. 237. U.S. Army Laboratories, Fort Detrick, MD.
23. Pollok, N. L. 1962. Mixed infections of Venezuelan equine encephalomyelitis and Q fever in Macaca mullata monkeys, p. 26. Technical memorandum no. 28. U.S. Army Biological Laboratories, Ft. Detrick, MD.
24. Scott, G. H., T. F. McCaul, and J. C. Williams. 1989. Inactivation of Coxiella burnetii by gamma irradiation. J. Gen. Microbiol. 135:3263-3270.
25. Smadel, J. E., M. J. Snyder, and F. C. Robins. 1948. Vaccination against Q fever. Am. J. Hyg. 47:71-78.
26. Spicer, D. S., and A. N. DeSanctis. 1976. Preparation of phase 1 Q fever antigen suitable for vaccine use. Appl. Environ. Microbiol. 32:85-88.
27. Stoker, M. G. P. 1957. Q fever down the drain. Br. Med. J. 1:425-427.
28. Tigertt, W. D. 1959. Studies on Q fever in man, p. 39. In J. E. Smadel (ed.), Symposium on Q fever, vol. 6. U.S. Government Printing Office, Washington, DC.
29. Tsai, C. M., and C. E. Frasch. 1982. A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119:115-119.
30. Uhaa, I. J., D. B. Fishbein, J. G. Olson, C. C. Rives, D. M. Waag, and J. C. Williams. 1994. Evaluation of specificity of indirect enzyme-linked immunosorbent assay for diagnosis of human Q fever. J. Clin. Microbiol. 32:1560-1565.
31. Vivona, S., J. P. Lowenthal, S. Berman, A. S. Benenson, and J. E. Smadel. 1964. Report of a field study with Q fever vaccine. Am. J. Hyg. 79:143-153.
32. Waag, D., J. Chulay, T. Marrie, M. England, and J. Williams. 1995. Validation of an enzyme immunoassay for serodiagnosis of acute Q fever. Eur. J. Clin. Microbiol. Infect. Dis. 14:421-427.
33. Waag, D. M., C. R. Bolt, T. J. Marrie, and J. C. Williams. 1991. Specific responses of humans to Coxiella burnetii: specific antibody and cell-mediated responses after vaccination or infection, p. 157-173. In J. C. Williams and H. A. Thompson (ed.), Q fever: the biology of Coxiella burnetii. CRC Press, Boca Raton, FL.
34. Waag, D. M., M. J. England, and M. L. Pitt. 1997. Comparative efficacy of a Coxiella burnetii chloroform:methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol. Vaccine 15:1779-1783.
35. Waag, D. M., K. T. McKee, Jr., G. Sandstrom, L. L. Pratt, C. R. Bolt, M. J. England, G. O. Nelson, and J. C. Williams. 1995. Cell-mediated and humoral immune responses after vaccination of human volunteers with the live vaccine strain of Francisella tularensis. Clin. Diagn. Lab Immunol. 2:143-148.
36. Wachter, R. F., G. P. Briggs, and C. E. Pedersen, Jr. 1978. Enhancement of the immunogenicity of phase I antigen of Coxiella burnetii. Infect. Immun. 22:627-628.
37. Wilhelmsen, C. L., and D. M. Waag. 2000. Guinea pig abscess/hypersensitivity model for study of adverse vaccination reactions induced by use of Q fever vaccines. Comp. Med. 50:374-378.
38. Williams, J. C., and J. L. Cantrell. 1982. Biological and immunological properties of Coxiella burnetii vaccines in C57BL/10ScN endotoxin-nonresponder mice. Infect. Immun. 35:1091-1102.
39. Williams, J. C., T. A. Damrow, D. M. Waag, and K. Amano. 1986. Characterization of a phase I Coxiella burnetii chloroform-methanol residue vaccine that induces active immunity against Q fever in C57BL/10 ScN mice. Infect. Immun. 51:851-858.
40. Williams, J. C., T. A. Hoover, D. M. Waag, N. Banerjee-Bhatnagar, C. R. Bolt, and G. H. Scott. 1990. Antigenic structure of Coxiella burnetii. A comparison of lipopolysaccharide and protein antigens as vaccines against Q fever. Ann. N. Y. Acad. Sci. 590:370-380.
41. Williams, J. C., M. G. Peacock, and T. F. McCaul. 1981. Immunological and biological characterization of Coxiella burnetii, phases I and II, separated from host components. Infect. Immun. 32:840-851.
42. Williams, J. C., M. G. Peacock, D. M. Waag, G. Kent, M. J. England, G. Nelson, and E. H. Stephenson. 1992. Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetii for the immunization of animals. Ann. N. Y. Acad. Sci. 653:88-111.
43. Williams, J. C., L. A. Thomas, and M. G. Peacock. 1986. Identification of phase-specific antigenic fractions of Coxiella burnetii by enzyme-linked immunosorbent assay. J. Clin. Microbiol. 24:929-934.